



**THE FOUNDATION
FOR SECURE
MARKETS®**

#55916

Date: January 16, 2025

Subject: ALVR1 Options - Expiration Pricing Consideration

ALVR1 (adjusted AlloVir, Inc. options) will be subject to special pricing consideration in expiration processing on January 17, 2025. The pricing consideration is due to the undetermined cash in lieu of fractional shares amount included in the option deliverable of ALVR1 as indicated below. These options will continue to be subject to normal exercise based on customary exercise thresholds in OCC's Ex-by-Ex processing.

MEMBERS SHOULD ADVISE THEIR CUSTOMERS TO TAKE THE FOLLOWING CONSIDERATIONS INTO ACCOUNT IN DECIDING TO EXERCISE, OR NOT TO EXERCISE, THESE OPTIONS.

ALVR1

ALVR1 options are adjusted AlloVir, Inc. options, adjusted January 16, 2025 (see OCC Information Memo #55899). The deliverable of ALVR1 options is:

NEW DELIVERABLE

PER CONTRACT:

- 1) 4 AlloVir, Inc. (ALVR) Common Shares
- 2) Cash in lieu of approximately 0.3478 fractional ALVR Shares

As of January 16, 2025, the ALVR Exchange Agent has not determined the price to be used to determine the cash in lieu amount.

For purposes of calculating a ALVR1 price for use in expiration processing, OCC will use the following formula:

$$\text{ALVR1} = 0.043478 (\text{ALVR})$$

For example, if ALVR closes at 8.47, the ALVR1 price would be:

$$\text{ALVR1} = 0.043478 (8.47) = 0.37$$

This formula includes an estimate for the value of the cash in lieu amount and not the actual amount applicable in the reverse split.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com.

Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theooc.com.